IL23A and neoplasm: Although the mechanisms underlying these biological activities are not fully understood and the interpretation of pre‐clinical studies on the involvement of IL‐12 and IL‐23 in tumor biology is not univocal, clinical studies indicate IL‐23 inhibitors as drugs with a good safety profile.